Aytu BioPharma, Inc.
AYTUNASDAQHealthcare● Active
$2.29
+$0.04(+1.78%)
Market Cap$18547399
P/E Ratio—
52W High$3.07
52W Low$1.65
Aytu BioPharma, Inc. (AYTU) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AYTU · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $66.38M | $65.18M | $107.40M | $96.67M | $65.63M |
| Cost of Revenue | $20.55M | $16.13M | $40.77M | $46.39M | $36.43M |
| Gross Profit | $45.83M | $49.05M | $66.63M | $50.28M | $29.20M |
| Gross Margin %(computed) | 69.04% | 75.26% | 62.04% | 52.02% | 44.49% |
| Operating Expenses | |||||
| R&D Expenses | $1.33M | $2.77M | $4.09M | $12.66M | $5.62M |
| G&A Expenses | $17.38M | $19.95M | $28.63M | $31.17M | $25.50M |
| Total Operating Expenses | $53.66M | $50.65M | $83.70M | $160.19M | $88.07M |
| Operating Income | ($7.83M) | ($1.59M) | ($17.07M) | ($109.91M) | ($58.87M) |
| Operating Margin %(computed) | -11.79% | -2.44% | -15.89% | -113.69% | -89.70% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.01M | $0.00M |
| Interest Expense | $3.70M | $4.79M | $4.96M | $147.50M | $0.00M |
| Income Before Tax | ($13.74M) | ($10.38M) | ($17.05M) | ($108.89M) | ($58.03M) |
| Income Tax Expense | $0.44M | $2.14M | $0.00M | ($0.11M) | $0.26M |
| Net Income | ($13.56M) | ($15.84M) | ($17.05M) | ($108.78M) | ($58.29M) |
| Net Margin %(computed) | -20.43% | -24.31% | -15.88% | -112.53% | -88.81% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-69.60 |
| Wtd Avg Shares | 6.28M | 5.54M | 3.34M | 1.47M | 0.84M |
| EBITDA | ($4.67M) | $1.41M | ($3.27M) | ($27.96M) | ($29.04M) |
| EBITDA Margin %(computed) | -7.03% | 2.16% | -3.05% | -28.92% | -44.25% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Aytu BioPharma, Inc. data
About Aytu BioPharma, Inc. (AYTU) Income Statement
Aytu BioPharma, Inc. (AYTU) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AYTU reported revenue of $0.07B, gross profit of $0.05B (gross margin 69.04%), and net income of ($0.01B) — a net profit margin of -20.43%.
Frequently asked questions
AYTU · 4 questionsAytu BioPharma, Inc. (AYTU) reported revenue of $0.07B for 2025, up 1.8% year-over-year.
AYTU revenueAYTU salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09